![Biocryst Pharmaceuticals Stock Forecast: up to 6.510 USD! - BCRX Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis Biocryst Pharmaceuticals Stock Forecast: up to 6.510 USD! - BCRX Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis](https://walletinvestorstorage.b-cdn.net/forecast-graphs/63/stock-bcrx-stock-forecast-components.png?v=1698696095)
Biocryst Pharmaceuticals Stock Forecast: up to 6.510 USD! - BCRX Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis
![BCRX - Biocryst Pharmaceuticals Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ) BCRX - Biocryst Pharmaceuticals Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)](https://images.fintel.io/us-bcrx-put-call-ratio.png)
BCRX - Biocryst Pharmaceuticals Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)
![Durham-based BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) licensed its recently approved flu treatment to Australia's CSL - Triangle Business Journal Durham-based BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) licensed its recently approved flu treatment to Australia's CSL - Triangle Business Journal](https://media.bizj.us/view/img/2741971/jon-p-stonehouse.jpg)
Durham-based BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) licensed its recently approved flu treatment to Australia's CSL - Triangle Business Journal
![BCRX - Biocryst Pharmaceuticals Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ) BCRX - Biocryst Pharmaceuticals Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)](https://images.fintel.io/us-bcrx-so.png)